PreciseInhale® 霧化器提供氣溶膠霧化全方面解決方案不論是干粉、DPIs、pMDIs抑或是其他液體氣溶膠均可以完成精確的氣溶膠控制并可適用于各種氣溶膠暴露實驗如口鼻吸入、氣管內(nèi)吸入、細胞染毒、離體肺臟、人工血氣屏障研究等。

PreciseInhale® 能夠快速而精確的控制氣溶膠生成并提供精確且有前瞻性劑量數(shù)據(jù)很大限度減少在體或體外實驗誤差降低風險。

產(chǎn)品特點

· 標準偏差小氣溶膠數(shù)據(jù)的典型標準偏差＜10%而傳統(tǒng)方法甚至高達 99%；

· 藥物消耗量低僅需 100mg 或更少的藥物就可以進行完整的藥動學實驗降低珍貴藥物消耗；

· 質(zhì)量而非數(shù)量體外模塊可以針對單只動物藥物劑量進行高精度控制并提供精確清晰的劑量數(shù)據(jù)節(jié)省動物用量；

· 氣溶膠顆粒均勻體內(nèi)外模塊均可產(chǎn)生均勻氣溶膠顆粒并可很大限度減少檢測誤差產(chǎn)生可比較性數(shù)據(jù)。

與高壓噴射不同PreciseInhale且精確的給藥方法可產(chǎn)生溫和可控的氣溶膠流從而能夠持續(xù)控制和監(jiān)測氣溶膠濃度以及每只動物的呼吸模式。

參考文獻

1.Delivering horseradish peroxidase as a respirable powder to the isolated, perfused, and ventilated lung of the ratthe pulmonary disposition of an inhaled model pharmaceutical；

PreciseInhale® – Isolated Perfused Lung (IPL)

2.Investigation of Lung Pharmacokinetic of the Novel PDE4 Inhibitor CHF6001 in Preclinical ModelsEvaluation of the PreciseInhale Technology；

PreciseInhale® – Isolated Perfused Lung (IPL)

3.Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivothe pulmonary pharmacokinetics of fluticasone furoate；

PreciseInhale® – Isolated Perfused Lung (IPL)

4.In Vitro to ex Vivo/In Vivo Correlation (IVIVC) of dissolution kinetics from inhaled particulate solutes using air/blood barrier modelsRelation between in vitro design, lung physiology and kinetic output of models；

DissolvIt® – Dissolution tests

5.Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivothe pulmonary pharmacokinetics of fluticasone furoate

PreciseInhale® – in vivo exposure